Business Wire

MN-CARGILL

1.2.2024 07:04:08 CET | Business Wire | Press release

Share
Cargill becomes first global edible oils supplier to meet World Health Organization’s best practice on eliminating industrially produced trans-fatty acids

As of Jan. 1, 2024, every Cargill food customer, no matter where they are in the world, can be confident that the company’s fats and oils comply with the World Health Organization’s (WHO) recommended maximum tolerance level for industrially produced trans-fatty acids (iTFA) in fats and oils. Cargill has achieved this milestone by becoming the first global supplier whose entire worldwide edible oils portfolio meets the WHO’s best practice standard on iTFAs, limiting iTFA content to no more than two grams per 100 grams of fats/oils, including in countries where there is currently no legislative mandate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131485973/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cargill has helped hundreds of customers reformulate and innovate nutritious and tasty products that meet WHO standards on iTFA (Photo: Business Wire)

While Cargill announced its commitment to removing iTFAs from its fats and oils portfolio in December 2021, the achievement reflects decades of work. The company’s iTFA journey spans more than a quarter century including early innovation, millions of dollars of investments in capital expenses and resources, and thousands of R&D hours. Along the way, Cargill has helped more than 400 customers create nutritious and tasty products that contribute to happier, healthier lives, removing more than 1.5 billion pounds of products containing iTFAs from the global food supply.

“We’re pleased to see Cargill’s continued commitment to reduce industrially produced trans fats in all their oils, recently achieving their goal to align with the World Health Organization’s recommended standards,” says René Lammers, PepsiCo’s chief science officer. “This move aligns with PepsiCo’s successful reduction of iTFAs in our foods to meet this same standard, and we encourage our fellow industry partners to join us in this important initiative to evolve our food and beverage portfolio to be better for the planet and people.”

In the past two years alone, Cargill has invested an additional $8.5 million to upgrade facilities to reduce the amount of transfat produced during oil processing, while working closely with more than 100 additional customers in two dozen countries to reformulate new product solutions that meet their needs.

iTFAs are most often formed through the partial hydrogenation of vegetable oils (PHOs) but can also be created by high thermal treatment during edible oil refining. In 2018, the WHO called for the global elimination of iTFAs by 2023, noting that trans fats intake greater than 1 percent of total energy intake is associated with coronary heart disease events and mortality.

"We’re extremely proud that we’ve met our commitment and helped fulfill our purpose -- nourishing the world in a safe, responsible and sustainable way,” said Natasha Orlova, Cargill vice president for edible oils and managing director for North America. “Taking this industry-leading step, even in countries without current iTFA legislation, helps ensure consistency in their supply chain for larger food manufacturers, while offering Cargill’s breadth of innovation and experience to smaller manufacturers.”

To ensure compliance, Cargill has added iTFAs to its larger food safety and quality assurance program. This systems-based approach includes multiple layers of monitoring, compliance and auditing.

In its latest progress report, the WHO noted that policies limiting the use of iTFAs have only been implemented in 60 of the world’s countries, covering approximately 43% of the global population. This leaves the majority of the world’s consumers at risk for continued iTFA consumption. The report called on major suppliers of oils and fats to “follow the pioneering effort of Cargill to remove industrially produced TFA from the products that are sold to food manufacturers globally.”1

“We are the first and only global edible oil supplier to commit to and meet the WHO standards consistently and across the board for our full global portfolio, and while we are understandably proud of this milestone, the WHO report highlights that much work remains,” Orlova said. “We have proven it is not only feasible to meet the iTFA recommendations while being mindful of saturated fat levels, but it can also be done without discernably changing the taste or texture of consumers’ favorite foods. We call upon other industry players to follow our lead and remove iTFAs from all their products, too.”

Cargill has also taken steps to help advance industry-wide reformulation during the past two years, particularly in countries that did not have iTFA regulation at the time of the company’s commitment. Among its actions, in Pakistan, Cargill partnered with the Sustainable Development Policy Institute on a public awareness campaign. In Malaysia and Mexico, the company interacted with industry, academic and government stakeholders to raise awareness of WHO best practices, while sharing experiences and expertise in iTFA reformulation.

1 “Countdown to 2023: WHO Report on Global Trans Fat Elimination,” World Health Organization, 2022. Download at: https://www.who.int/publications/i/item/9789240067233

About Cargill

Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.

Our 160,000 team members innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 159 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131485973/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye